Key facts
- This page summarizes Christopher M. Murphy's Form 4 filing for Third Harmonic Bio, Inc. (THRD).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Jan 2025, 18:10.
Christopher M. Murphy - 15 Jan 2025 Form 4 Insider Report for Third Harmonic Bio, Inc. (THRD)
- Reporting relationship
- Chief Financial & Bus. Officer
- Issuer ticker
- THRD
- Reported as of
- 15 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jan 2025, 18:10:34 UTC
- Prior SEC filing
- 09 Jan 2024
- Next SEC filing
- 05 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Murphy
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher M. Murphy filed Form 4 for Third Harmonic Bio, Inc. (THRD) on 17 Jan 2025.
Change
- Previous filing in this sequence was filed on 09 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
THRD
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +140,000
- Change %
- Price
- $0.000000
- Shares after
- 140,000
- Date
- 15 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 140,000
- Exercise price
- $6.00
- Footnotes
- F1, F2
THRD
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +17,500
- Change %
- Price
- $0.000000
- Shares after
- 17,500
- Date
- 15 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,500
- Exercise price
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The equity awards of the Reporting Person in this Form 4 were approved on December 17, 2024 by the board of directors as part of the annual refresh equity grant process of the registrant with an effective grant date of January 15, 2025.
Footnote F2
The option vests over a four-year period: 2.0833% shall vest on February 15, 2025, after which 2.0833% of the total shares vest monthly, subject to contioued service through each vestiog date.
Footnote F3
Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Footnote F4
The RSU vests over a four-year period: 1/4 on Febuary 15, 2026, after which 1/4 of the total shares vest annually, subject to contioued service through each vestiog date.